ridaforolimus + doxorubicin

Ridaforolimus + doxorubicin is a combination therapy investigated for the treatment of various advanced solid tumors, including soft-tissue sarcomas, breast, ovarian, and endometrial cancers. Ridaforolimus (formerly known as deforolimus, AP23573, or MK-8669) is a small molecule inhibitor of the mammalian target of rapamycin (mTOR), a serine/threonine kinase that serves as a central regulator of cell growth, proliferation, and survival. Doxorubicin is a well-established anthracycline chemotherapy agent that works by intercalating DNA and inhibiting the enzyme topoisomerase II, leading to DNA damage and cell death. The combination was developed through a collaboration between ARIAD Pharmaceuticals and Merck, with the goal of enhancing the efficacy of chemotherapy by co-targeting the mTOR signaling pathway. Clinical evaluation reached Phase Ib (NCT00288431), but development was ultimately discontinued following the broader termination of the ridaforolimus program.

Other names

ridaforolimus + doxorubicindeforolimus + doxorubicinAP23573 + doxorubicinMK-8669 + doxorubicin